Therapy Areas: Infectious Diseases
Novavax names new SVP, chief safety officer and head of Global Vaccine Safety
5 October 2021 -

Novavax Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercialising next-generation vaccines for serious infectious diseases, announced on Monday that it has named Denny Kim, M.D., MPH as its new senior vice president, chief safety officer and head of Global Vaccine Safety.

Dr Kim is to report to Filip Dubovsky, M.D., MPH, FAAP, executive vice president and chief medical officer.

Dr Kim has around two decades of infectious disease, clinical trial and safety experience. He has served at Johnson & Johnson, where he was part of the office of the chief medical officer. He built and headed the global Patient Safety and Pharmacovigilance function at Horizon Pharma, developed a new safety function within Takeda's Vaccine Business Unit, and held the position of therapeutic area safety head at both Takeda and Astellas.



Related Headlines